226 related articles for article (PubMed ID: 22397732)
1. Radiovirotherapy: principles and prospects in oncology.
Touchefeu Y; Franken P; Harrington KJ
Curr Pharm Des; 2012; 18(22):3313-20. PubMed ID: 22397732
[TBL] [Abstract][Full Text] [Related]
2. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
3. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).
Opyrchal M; Allen C; Iankov I; Aderca I; Schroeder M; Sarkaria J; Galanis E
Hum Gene Ther; 2012 Apr; 23(4):419-27. PubMed ID: 22185260
[TBL] [Abstract][Full Text] [Related]
4. The use of the NIS reporter gene for optimizing oncolytic virotherapy.
Miller A; Russell SJ
Expert Opin Biol Ther; 2016; 16(1):15-32. PubMed ID: 26457362
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H; Peng KW; Russell SJ
Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
[TBL] [Abstract][Full Text] [Related]
6. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
7.
Jung MY; Offord CP; Ennis MK; Kemler I; Neuhauser C; Dingli D
Cancer Res; 2018 Oct; 78(20):5992-6000. PubMed ID: 30115692
[TBL] [Abstract][Full Text] [Related]
8. Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.
Touchefeu Y; Khan AA; Borst G; Zaidi SH; McLaughlin M; Roulstone V; Mansfield D; Kyula J; Pencavel T; Karapanagiotou EM; Clayton J; Federspiel MJ; Russell SJ; Garrett M; Collins I; Harrington KJ
Radiother Oncol; 2013 Jul; 108(1):24-31. PubMed ID: 23849174
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E
Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744
[TBL] [Abstract][Full Text] [Related]
10. [Measles virus: a future therapeutic agent in oncology?].
Touchefeu Y; Schick U; Harrington KJ
Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
12. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.
Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ
Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101
[TBL] [Abstract][Full Text] [Related]
13. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
14. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.
Trujillo MA; Oneal MJ; McDonough S; Qin R; Morris JC
Cancer Gene Ther; 2012 Dec; 19(12):839-44. PubMed ID: 23037808
[TBL] [Abstract][Full Text] [Related]
15. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
17. Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy.
Trujillo MA; Oneal MJ; McDonough SJ; Morris JC
Gene Ther; 2013 May; 20(5):567-74. PubMed ID: 22972493
[TBL] [Abstract][Full Text] [Related]
18. Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus.
Grünwald GK; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Göke B; Holm PS; Spitzweg C
Gene Ther; 2013 Jun; 20(6):625-33. PubMed ID: 23038026
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modeling of cancer radiovirotherapy.
Dingli D; Cascino MD; Josić K; Russell SJ; Bajzer Z
Math Biosci; 2006 Jan; 199(1):55-78. PubMed ID: 16376950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
